Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

Yes For Shionogi But No For Lilly In Latest EMA Recommendations

The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.

Europe Approvals

Xarelto And Eylea Keep Bayer Buoyant

The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.

Companies Legal Issues

Apple And J&J Collaborate On Large Atrial Fibrillation Study

The Heartline Study is evaluating how the Apple Watch can identify and predict atrial fibrillation while improving cardiovascular outcomes and patients’ adherence to anticoagulant drugs.

Clinical Trials Digital Health

Generics Firms Deterred From Continuous Manufacturing

Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.

Manufacturing Generic Drugs
See All

Company Information

UsernamePublicRestriction

Register